Antony Mattessich named next CEO of Ocular Therapeutix

Antony Mattessich will take over as CEO of Ocular Therapeutix by Sept. 30, according to a company press release.

Mattessich succeeds Amar Sawhney, PhD, current CEO and chairman of the board of directors, who will transition to an executive chairman role, the release said. Mattessich has also been elected to the board of directors.

“Antony has over 25 years of experience building, managing and growing global pharmaceutical organizations to large, successful companies and brands. We are fortunate to be able to attract someone of his caliber to lead Ocular,” Sawhney said in the release. “In my capacity as executive chairman of the board, I will continue to provide Ocular Therapeutix with my input and expertise to facilitate continuity and a smooth transition as we head to this exciting new phase for the company.”

Mattessich previously worked for multiple pharmaceutical companies including Novartis, Bristol Meyers Squibb and Merck & Co., most recently serving as managing director of Mundipharma.

“It is an exciting time to join Ocular Therapeutix,” he said in the release. “I believe the company has tremendous potential, and I look forward to applying my expertise to advancing Ocular’s robust pipeline of product candidates that the team has built under Amar’s guidance.”